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Non-Tuberculous Mycobacterial Pulmonary Disease 
identified during community-based screening for 
Mycobacterium Tuberculosis: a case report
Case Report
Abstract
There is a rising prevalence of  Non-Tuberculous Mycobacterial (NTM) disease in sub-Saharan Africa identified on culture specimens. 
However, distinguishing mycobacterial colonisations from infection from identified NTMs on culture in the sub-Saharan Africa 
setting remains to be established. A 49-year-old man presented with the cardinal symptoms of  tuberculosis (TB) in a community TB 
prevalence survey in Blantyre, Malawi. Mycobacteriology was atypical, prompting a line probe assay which revealed Mycobacterium 
avium complex (MAC) species.  
The epidemiology of  Mycobacterium tuberculosis complex (MTBC) is better known than that of  NTM. Up-scaling culture and speciation 
may be a solution to this gap in knowledge of  the burden of  disease of  NTM. Like most resource-poor settings, TB culture is not 
routinely done in the diagnosis and management of  TB in Malawi. Furthermore, the treatment of  NTM is not analogous to that 
of  MTBC. The multi-drug regimens used for NTM disease treatment includes a newer macrolide (azithromycin, clarithromycin), 
ethambutol, and rifamycin, and require prolonged durations of  therapy aimed at facilitating clearance of  the mycobacteria and 
minimizing the emergence of  drug resistance. Clinicians must thus be aware of  this rising burden of  NTM disease and consider other 
diagnostic options to better investigate this disease in patients.
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Background
All members of  the genus Mycobacterium other than the 
Mycobacterium tuberculosis complex (MTBC) and Mycobacterium 
leprae are collectively labelled nontuberculous mycobacteria 
(NTM). Among the NTM, the members of  the Mycobacterium 
avium complex (MAC) are the most frequent causative agents of  
human disease and can cause chronic pulmonary infections 
in adults, lymphadenitis in children and extrapulmonary 
and disseminated infections in the systemically 
immunocompromised1. MAC infections are caused by either 
Mycobacterium avium or Mycobacterium intracellulare1. 
NTM disease not a notifiable disease in most countries2, 
making it difficult to estimate the global burden of  NTM 
disease. Isolated studies from Europe, North America and 
Asia suggest a prevalence of  NTM disease ranging from 
2.9 cases per 100,000 population to 16 cases per 100,000 
population2. Data on the burden of  NTM disease in sub-
Saharan Africa is even more scarce3,4. The few studies on 
NTM show a rising prevalence of  the disease identified 
on culture specimens4,5. However, the clinical relevance of  
the NTMs in the sub-Saharan Africa setting remains to be 
established3.
Case presentation
A 49 -year-old male was recruited for a community-based 
tuberculosis (TB) prevalence survey in Blantyre, Malawi. 
The TB prevalence survey was part of  the larger SCALE 
Trial (Registration Number: ISRCTN11400592), which 
investigated the effect of  community-wide active door-to-
door screening for tuberculosis. The prevalence survey was 
conducted between 26 May 2019 and 31 March 2020 in 72 
clusters around peri-urban Blantyre. The patient was recently 
diagnosed with HIV and had been on antiretroviral therapy 
(ART) for 5 months. He had complaints of  productive 
cough, night sweats, weight loss, malaise and joint pains for 
two months. On physical examination he was afebrile, had a 
respiratory rate of  19bpm, a pulse rate of  113bpm and blood 
pressure of  143/72mmHg. His lungs were clear and he had 
no cardiac gallop, murmurs or rubs. Abdominal examination 
was normal and he had no pedal oedema.
Chest X-rays were normal. Sputum microscopy revealed 3+ 
acid fast bacilli with highly beaded long, thin bacilli, but Gene 
Xpert MTB/RIF was negative. Confirmatory testing yielded 
2+ AFB but negative Gene Xpert MTB/RIF. Both initial 
and confirmatory samples were grown in Microbacterium 
Growth Indicator Tubes (MGIT) containing Middlebrook 
7H9 media. Positive cultures were confirmed by Ziehl-
Neelsen (ZN) stain and an antigen identification test (BD 
MGIT TBc). In both circumstances ZN was positive and 
antigen test negative. Cultures were then grown on 3 plain 
Loweinstein-Jensen (LJ) media and 1 para-nitrobenzoic acid 
(PNB) LJ media and then incubated at different temperatures 
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(25oC, 37oC, 45oC and 37oC PNB LJ), with a positive 
confirmatory ZN stain but a negative antigen test and 
atypical atypical mycobacterial morphology (figure 1A, B). 
The sample was run through the GenoType Mycobacterium 
(Hain Lifescience, Nehren, Germany) line probe assay (LPA), 
which revealed Mycobacterium avium complex (MAC). The 
patient had been started on standard TB treatment regimen 
of  Rifampicin, Isoniazid, Pyrazinamide and Ethambutol 
(RHZE), which greatly improved his symptoms over 4 
weeks. He was then traced and azithromycin 500mg thrice 
weekly was added to his treatment. 
Discussion
The epidemiology of  MTBC is better known than that of  
NTM. A review in 2017 by Okoi et al. described the overall 
prevalence of  NTM in pulmonary samples in sub-Saharan 
Africa to be 7.5% (95% CI: 7.2–7.8 %)4. Another study in 
Botswana demonstrated that among culture-positive sputum 
specimens collected from people living with HIV (PLHIV) 
with TB symptoms, 56% grew NTM6. To our knowledge, 
there is little knowledge about the prevalence of  NTM 
disease in Malawi, which may be a result of  the difficulties 
in diagnosing NTM using the conventional methods in place 
for detecting MTB disease1.  
Upscaling culture and speciation may be a solution to this 
gap in knowledge of  the burden of  disease of  NTM. The 
mainstay of  diagnosing TB in low-resource TB endemic 
countries like Malawi is smear microscopy7–9, with additional 
tests like Xpert MTB/RIF and urine lipoarabinomannan 
(LAM) assays being integrated in the diagnostic pathway in 
recent years8. These tests are unable to distinguish between 
MTBC and NTM. TB culture and speciation are based in 
specialist centres and reference laboratories, and not easily 
accessible for the general population8.
The treatment of  NTM is not analogous to that of  MTBC. 
The multi-drug regimens used for NTM disease treatment 
includes a newer macrolide (azithromycin, clarithromycin), 
ethambutol, and rifamycin, and require prolonged 
durations of  therapy aimed at facilitating clearance of  
the mycobacteria and minimizing the emergence of  drug 
resistance1. Misdiagnosing the disease may thus result in poor 
treatment outcomes, prompting clinicians to retreat patients 
for TB relapse, further driving emergence of  antimicrobial 
resistance. 
Another question that arises from this study concerns the 
applicability of  the ATS case-definitions for pulmonary 
NTM disease in populations with a high incidence of  M. 
tuberculosis disease. The ATS criteria for diagnosing 
MAC requires identification of  cavities/nodules on 
plain radiograph, or having a high-resolution computed 
tomography scan that shows multifocal bronchiectasis with 
multiple small nodules1. Though plain radiography is widely 
available in the referral hospitals in Malawi, there is no 
guarantee that any abnormalities will be present. A previous 
review of  the radiographic features of  Mycobacterium 
avium complex revealed that up to 21% of  the radiographs 
from immunocompromised patients may be normal and the 
classic radiographic appearance is indistinguishable from 
that of  pulmonary tuberculosis10.
The ATS criteria does not include Xpert MTB/RIF in its 
diagnostic algorithm. GeneXpert is significantly sensitive for 
Mycobacterium tuberculosis complex (MTBC)11, and has a high 
specificity (98.6%),6 which could potentially allow the test 
to be used to exclude MTBC when negative in a patient with 
AFB positivity on ZN stain. The newer version of  Xpert 
MTB/RIF, Xpert Ultra, has an even higher sensitivity, though 
at a cost of  some specificity12, and could be a tool to drive 
further investigation for patients who are smear positive but 
Xpert negative.  This could allow for possible cases of  NTM 
to be described, prompting cultures in patients that would 
have otherwise just been treated as MTBC. 
In conclusion, there is a diagnostic gap with regards to culture 
and speciation services for Mycobacterium tuberculosis 
in low resource health care facilities. Upscaling of  culture 
and speciation services at all levels of  health care in Malawi 
may enable diagnosing NTM disease, prompting targeted 
treatment options with potentially better outcomes. Further 
studies are required to investigate the burden of  NTM 
disease in Malawi, as well as investigate the timing of  ART 
initiation in cases of  NTM disease and the interaction of  
ARTs and NTM disease medications.
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Figure 1. Images of the microbiological tests done for the patient. 
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